No Matches Found
No Matches Found
No Matches Found
Genpact Ltd.
Genpact Stock Plummets to New 52-Week Low at $33.54
Genpact has reached a new 52-week low, trading at USD 33.54, reflecting a notable decline for the small-cap company. Despite this, it maintains a low price-to-earnings ratio and strong financial metrics, including a solid return on equity and low debt-to-equity ratio, indicating potential for long-term growth.
Genpact Stock Plummets to New 52-Week Low at $33.67
Genpact has reached a new 52-week low of USD 33.67, reflecting a notable decline despite a modest annual return of 2.89%. The company, with a market cap of USD 6,540 million, demonstrates strong management efficiency and low leverage, alongside healthy long-term growth and a high dividend yield.
Genpact Stock Plummets to New 52-Week Low at $33.74
Genpact has hit a new 52-week low, trading at USD 33.74, reflecting a notable decline for the small-cap company. Despite a modest annual return of 4.38%, it maintains a strong P/E ratio of 12.00, a solid return on equity of 22.31%, and a low debt-to-equity ratio of 0.15.
Genpact Forms Death Cross, Signaling Potential Bearish Trend Ahead
Genpact Ltd. has recently encountered a Death Cross, indicating a potential shift in market sentiment. Technical indicators suggest a bearish outlook, yet the stock has shown resilience with a slight daily increase. Over the past year, Genpact has struggled, significantly underperforming compared to the S&P 500.
Genpact Ltd. Experiences Evaluation Revision Amid Mixed Market Performance Indicators
Genpact Ltd. has recently revised its evaluation amid challenging market conditions, with its stock price showing a slight increase. Over the past year, the company has experienced a significant decline, contrasting with broader market gains. Technical indicators present a mixed outlook, reflecting ongoing market indecision.
Genpact Ltd. Hits Day High with 15.89% Surge in Stock Price
Genpact Ltd. saw a notable rise in its stock price on November 7, 2025, reaching an intraday high. The company has demonstrated strong short-term performance, although it has underperformed compared to the S&P 500 over the past year. Genpact maintains solid financial metrics, including high management efficiency and low debt levels.
Genpact Stock Plummets to New 52-Week Low at $37.50
Genpact has hit a new 52-week low of USD 37.50, reflecting a notable decline in its performance compared to the S&P 500. The company, with a market cap of USD 7,759 million, shows a low debt-to-equity ratio and high management efficiency, but its net profit has decreased significantly.
Genpact Stock Plummets to 52-Week Low at USD 37.77
Genpact has reached a new 52-week low, trading at USD 37.77, reflecting a notable decline for the small-cap company. Despite a low debt-to-equity ratio and strong management efficiency, its net profit has decreased significantly. The stock is trading at a discount compared to historical valuations.
Is Genpact Ltd. overvalued or undervalued?
As of October 17, 2025, Genpact Ltd. is fairly valued with a P/E ratio of 14 and has underperformed the S&P 500 over the last three years, returning -12.78% compared to the index's 81.19%.
Genpact Ltd. Experiences Revision in Its Stock Evaluation Amid Mixed Market Metrics
Genpact Ltd. has recently adjusted its valuation, with its stock price at $39.44. Over the past year, it has achieved a 2.49% return, lagging behind the S&P 500. Key metrics include a P/E ratio of 14, an EV to EBITDA ratio of 10.29, and a notable dividend yield of 150.00%.
Is Genpact Ltd. overvalued or undervalued?
As of October 17, 2025, Genpact Ltd. is fairly valued with a P/E ratio of 14 and has underperformed the S&P 500, showing a year-to-date return of -8.17% compared to the index's 13.30%.
Is Genpact Ltd. overvalued or undervalued?
As of October 17, 2025, Genpact Ltd. is fairly valued with a P/E ratio of 14 and has underperformed the S&P 500, showing a year-to-date return of -8.17% compared to the index's 13.30%.
Genpact Ltd. Experiences Revision in Its Stock Evaluation Amid Market Challenges
Genpact Ltd. has recently adjusted its technical trends, with its current price slightly lower than the previous close. Over the past year, the company has underperformed compared to the S&P 500. Various technical indicators suggest a predominantly bearish outlook, reflecting ongoing challenges in the market.
Is Genpact Ltd. technically bullish or bearish?
As of October 3, 2025, Genpact Ltd. is in a bearish trend, indicated by bearish momentum from the MACD and moving averages, despite a mildly bullish KST signal, and has underperformed the S&P 500 with a year-to-date return of -4.28%.
Is Genpact Ltd. technically bullish or bearish?
As of October 3, 2025, Genpact Ltd. has shifted to a bearish trend, supported by negative indicators like a bearish MACD and moving averages, despite a mildly bullish KST signal on the monthly, and has underperformed the S&P 500 with a year-to-date return of -4.05%.
Is Genpact Ltd. technically bullish or bearish?
As of October 3, 2025, Genpact Ltd. is in a bearish trend, indicated by bearish MACD and Bollinger Bands, despite a mildly bullish KST signal, and has underperformed the S&P 500 with a 1-month return of -8.83% compared to 4.15%.
Is Genpact Ltd. technically bullish or bearish?
As of September 8, 2025, Genpact Ltd. shows a mildly bearish technical trend, with bearish indicators from the MACD and moving averages, despite a mildly bullish KST, and has underperformed the S&P 500 significantly in recent periods.
Is Genpact Ltd. overvalued or undervalued?
As of July 7, 2025, Genpact Ltd. is fairly valued with a P/E ratio of 14, competitive EV to EBITDA ratio of 10.29, strong ROCE of 22.82% and ROE of 21.71%, despite underperforming the S&P 500 in recent years, indicating a potentially attractive investment opportunity.
Is Genpact Ltd. overvalued or undervalued?
As of February 6, 2025, Genpact Ltd. is fairly valued with a P/E ratio of 14, lower than some peers, indicating it may be undervalued relative to competitors, despite its recent stock performance outpacing the S&P 500 over the past year.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
